Insider Selling: Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells 1,576 Shares of Stock

Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal sold 1,576 shares of the business’s stock in a transaction dated Wednesday, June 9th. The stock was sold at an average price of $35.00, for a total value of $55,160.00. Following the sale, the chief executive officer now owns 5,000 shares of the company’s stock, valued at approximately $175,000. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lloyd Mitchell Segal also recently made the following trade(s):

  • On Friday, June 4th, Lloyd Mitchell Segal sold 5,000 shares of Repare Therapeutics stock. The stock was sold at an average price of $31.25, for a total value of $156,250.00.
  • On Thursday, May 20th, Lloyd Mitchell Segal sold 3,770 shares of Repare Therapeutics stock. The stock was sold at an average price of $35.03, for a total value of $132,063.10.
  • On Tuesday, May 18th, Lloyd Mitchell Segal sold 1,800 shares of Repare Therapeutics stock. The stock was sold at an average price of $35.00, for a total value of $63,000.00.
  • On Thursday, April 15th, Lloyd Mitchell Segal sold 5,512 shares of Repare Therapeutics stock. The stock was sold at an average price of $35.01, for a total value of $192,975.12.

NASDAQ:RPTX opened at $33.88 on Friday. Repare Therapeutics Inc. has a 1 year low of $21.45 and a 1 year high of $46.44. The company has a market capitalization of $1.25 billion and a PE ratio of -8.89. The stock has a fifty day simple moving average of $32.63.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings results on Thursday, May 13th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.07). The firm had revenue of $0.17 million during the quarter. On average, research analysts expect that Repare Therapeutics Inc. will post -2.44 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on the company. Berenberg Bank assumed coverage on Repare Therapeutics in a research report on Monday, March 1st. They issued a “buy” rating and a $51.00 target price on the stock. Zacks Investment Research raised Repare Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Morgan Stanley upped their price target on Repare Therapeutics from $41.00 to $45.00 and gave the company an “overweight” rating in a research report on Monday, April 19th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $40.20.

Large investors have recently added to or reduced their stakes in the company. Penserra Capital Management LLC bought a new position in Repare Therapeutics during the fourth quarter valued at about $28,000. Royal Bank of Canada lifted its holdings in shares of Repare Therapeutics by 86.0% during the first quarter. Royal Bank of Canada now owns 1,356 shares of the company’s stock valued at $41,000 after purchasing an additional 627 shares during the last quarter. Citigroup Inc. purchased a new stake in shares of Repare Therapeutics during the fourth quarter valued at $42,000. UBS Group AG increased its holdings in shares of Repare Therapeutics by 607.0% during the 1st quarter. UBS Group AG now owns 1,414 shares of the company’s stock valued at $43,000 after acquiring an additional 1,214 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Repare Therapeutics in the 1st quarter valued at approximately $46,000. 70.24% of the stock is owned by institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Read More: What are the qualifications of a portfolio manager?

Insider Buying and Selling by Quarter for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.